Abstract:Objective To estimate the clinical value of serum high mobility group box 1(HMGB1) as a biomarker of pulmonary arterial hypertension with congenital heart disease (CHD-PAH). Methods This study included 83 patients with pulmonary arterial hypertension associated with congenital heart disease in the Second Xiangya Hospital, Central South University from May 2013 to April 2015, and all the patients are divided into two groups according to mean pulmonary artery pressure(MPAP): congenital heart disease with mild-to-moderate pulmonary arterial hypertension group(group A1, n=23) and congenital heart disease with severe pulmonary arterial hypertension group(group A2, n=60). Then set two control groups: congenital heart disease without pulmonary arterial hypertension group(group B, n=23) and healthy adult control group(group C, n=20). Of all the patients with CHD-PAH, 18 were followed up for 6 months during treating with PAH-specific pharmacotherapies. All the subjects' clinical data were collected, cardiac catheterization and echocardiographs were performed. HMGB1 levels were determined by enzyme linked immunosorbent assay(ELISA). Results Serum HMGB1 levels were significantly increased in patients with CHD-PAH compared with CHD without PAH and control group(16.19±7.67 μg/L vs. 5.35±2.03 μg/L, 16.19±7.67 μg/L vs. 3.76±1.25 μg/L; P<0.05); Serum HMGB1 levels were significantly increased in patients with mild-to-moderate CHD-PAH group compared with severe CHD-PAH group(19.12±6.70 μg/L vs. 8.54±3.71 μg/L, P<0.05). The serum HMGB1 levels were significantly positive correlation with MPAP(r=0.864, P<0.05) in patients with CHD. After treating with PAH-specific pharmacotherapies for 6 month, HMGB1 levels were significantly decreased(18.12±5.31 μg/L vs. 13.51±1.47 μg/L, P<0.05) along with the patients' MPAP(65.1±10.1mmHg vs. 55.3±9.2 mmHg, P<0.05) and six minutes walk distances improved. Conclution Our study suggested that serum HMGB1 may be used as a biomarker to identify CHD-PAH, to assess the pulmonary vascular remodeling in patients with PAH. Furthermore, HMGB1 level was a marker of treatment response to targeted therapy so that it has the potential to be used as a biomarker in the follow-up evaluation of patients with CHD-PAH.

Clinical Value of ADMA in Patients with Pulmonary Arterial Hypertension Combination with Congenital Heart Disease

Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease.

Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Increased Serum Concentrations of Asymmetric Dimethylarginine (ADMA) in Patients with Early-Onset Coronary Artery Disease.

Role of Change of ADMA in Patients with Coronary Heart Disease

Correlation Between Plasma Asymmetric Dimethylarginine and Different Types of Coronary Heart Disease

Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

NMR-Based Metabolomic Analysis of Plasma in Patients with Adult Congenital Heart Disease and Associated Pulmonary Arterial Hypertension: A Pilot Study

Serum high mobility group box 1 levels and its clinical significance in patients with pulmonary arterial hypertension associated with congenital heart disease.

Expression and Role of Adrenomedullin and Its Receptor in Patients with Chronic Obstructive Pulmonary Disease.

Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease.

Protein Biomarkers And Risk Scores In Pulmonary Arterial Hypertension Associated With Ventricular Septal Defect: Integration Of Multi-Omics And Validation

Asymmetric dimethylarginine correlates with indicators of prethrombotic state in patients with nonvalvular atrial fibrillation

Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)

Increased cerebrospinal fluid concentrations of asymmetric dimethylarginine correlate with adverse clinical outcome in subarachnoid hemorrhage patients.

Clinical Significance of the Changes of Plasma Adiponectin Levels in Patients with Coronary Artery Disease

E-selectin and asymmetric dimethylarginine plasma levels in adult cyanotic congenital heart disease patients: relation to biochemical parameters, vascular function, and clinical status.

Levels of Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor, and Risk of Coronary Artery Disease: A Meta-Analysis Based on 4713 Participants.

Pulmonary Arterial Dimensions and Right Ventricular Function by Cardiac MRI